Inverse agonists and antagonists of retinoid receptors

Methods in Enzymology

Volumn 485, Issue C, 2010, Pages 161-195

  Bourguet, William ^a   de Lera, Angel R ^b   Gronemeyer, Hinrich ^c  

^a CENTRE DE BIOCHIMIE STRUCTURALE   (France)

^b UNIVERSITY OF VIGO   (Spain)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(1) 2 (5,5 DIMETHYL 8 (2 PHENYLETHYNYL) 5,6 DIHYDRONAPHTHALEN 2 YL)VIN 1 YL]BENZOIC ACID; 4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 4 [7 ADAMANTYL 6 [(2 METHOXYETHOXY)METHOXY] 2 NAPHTHYL]BENZOIC ACID; AGNI 192870; AGNI 193109; AGNI 193385; AGNI 193389; AGNI 193840; AGNI 194310; BMS 195614; BMS 204493; BMS 453; BMS 493; BMS 614; BMS 641; BMS 701; CARBOXYPEPTIDASE C; CD 3254; CELL NUCLEUS RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOID RECEPTOR; RETINOID X RECEPTOR; TRYPSIN; UNCLASSIFIED DRUG; UVI 3002; UVI 3003; VITAMIN RECEPTOR;

ANISOTROPY; BOOK; CELL ASSAY; CELL LINE; CYTOLYSIS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; FLUORESCENCE; HELA CELL; HUMAN; INVERSE AGONISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSIENT TRANSFECTION; TWO HYBRID SYSTEM;

EID: 78049491490     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381296-4.00010-5     Document Type: Chapter

References (68)

1. Alland L., Muhle R., Hou H., Potes J., Chin L., SchreiberAgus N., et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997, 387:49-55.
2. Álvarez S., Khanwalkar H., Álvarez R., Erb C., MartÌnez C., Rodríguez-Barrios F., et al. C3 halogen and C8" substituents on stilbene arotinoids modulate retinoic acid receptor subtype function. ChemMedChem 2009, 4:1630-1640.
3. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
4. Astapova I., Lee L.J., Morales C., Tauber S., Bilban M., Hollenberg A.N. The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo. Proc. Natl. Acad. Sci. USA 2008, 105:19544-19549.
5. Auffinger P., Hays F.A., Westhof E., Ho P.S. Halogen bonds in biological molecules. Proc. Natl. Acad. Sci. USA 2004, 101:16789-16794.
6. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996, 384:641-643.
7. Bourguet W., Germain P., Gronemeyer H. Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 2000, 21:381-388.
8. Bourguet W., Vivat V., Wurtz J.M., Chambon P., Gronemeyer H., Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 2000, 5:289-298.
9. Chen J.D., Evans R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995, 377:454-457.
10. Chen J.Y., Penco S., Ostrowski J., Balaguer P., Pons M., Starrett J.E., et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995, 14:1187-1197.
11. Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L., et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997, 90:569-580.
12. Chen D., Ma H., Hong H., Koh S.S., Huang S.M., Schurter B.T., et al. Regulation of transcription by a protein methyltransferase. Science 1999, 284:2174-2177.
13. Cohen R.N., Brzostek S., Kim B., Chorev M., Wondisford F.E., Hollenberg A.N. The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains. Mol. Endocrinol. 2001, 15:1049-1061.
14. Collingwood T.N., Urnov F.D., Wolffe A.P. Nuclear receptors: Coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endocrinol. 1999, 23:255-275.
15. de Lera A.R., Bourguet W., Altucci L., Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discov. 2007, 6:811-820.
16. de Meijere A., Diederich F. Metal-Catalyzed Cross-Coupling Reactions 2004, Weinheim, Wiley-VCH. 2nd edn.
17. Domínguez B., Alvarez R., de Lera A.R. Recent advances in the synthesis of retinoids. Org. Prep. Proc. Int. 2003, 35:239-306.
18. Evert B.O., Araujo J., Vieira-Saecker A.M., de Vos R.A., Harendza S., Klockgether T., et al. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci. 2006, 26:11474-11486.
19. García J., Khanwalkar H., Pereira R., Erb C., Voegel J.J., Collette P., et al. Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors. Chembiochem 2009, 10:1252-1259.
20. Gehin M., Vivat V., Wurtz J.M., Losson R., Chambon P., Moras D., et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem. Biol. 1999, 6:519-529.
21. Germain P., Iyer J., Zechel C., Gronemeyer H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 2002, 415:187-192.
22. Germain P., Kammerer S., Pérez E., Peluso-Iltis C., Tortolani D., Zusi F.C., et al. Rational design of RAR-selective ligands revealed by RARbeta crystal structure. EMBO Rep. 2004, 5:877-882.
23. Germain P., Gaudon C., Pogenberg V., Sanglier S., Van Dorsselaer A., Royer C.A., et al. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem. Biol. 2009, 16:479-489.
24. Glass C.K., Rose D.W., Rosenfeld M.G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 1997, 9:222-232.
25. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3:950-964.
26. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature 1997, 387:819-823.
27. Hanstein B., Eckner R., Di Renzo J., Halachmi S., Liu H., Searcy B., et al. p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. USA 1996, 93:11540-11545.
28. Hashimoto Y., Miyachi H. Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. Bioorg. Med. Chem. 2005, 13:5080-5093.
29. Heinzel T., Lavinsky R.M., Mullen T.M., Soderstrom M., Laherty C.D., Torchia J., et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 1997, 387:43-48.
30. Hong H., Kohli K., Garabedian M.J., Stallcup M.R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol. 1997, 17:2735-2744.
31. Horlein A.J., Naar A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995, 377:397-404.
32. Hu X., Lazar M.A. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 1999, 402:93-96.
33. Hu X., Li Y., Lazar M.A. Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. Mol. Cell. Biol. 2001, 21:1747-1758.
34. Huang P., Chandra V., Rastinejad F. Structural overview of the nuclear receptor superfamily: Insights into physiology and therapeutics. Annu. Rev. Physiol. 2010, 72:247-272.
35. Jepsen K., Solum D., Zhou T., McEvilly R.J., Kim H.J., Glass C.K., et al. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 2007, 450:415-419.
36. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:403-414.
37. Klein E.S., Pino M.E., Johnson A.T., Davies P.J.A., Nagpal S., Thacher S.M., et al. Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J. Biol. Chem. 1996, 271:22692-22696.
38. Korzus E., Torchia J., Rose D.W., Xu L., Kurokawa R., McInerney E.M., et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998, 279:703-707.
39. Laudet V., Gronemeyer H. The Nuclear Receptor Factsbook 2001, Academic Press, San Diego, 462 pp.
40. le Maire A., Teyssier C., Erb C., Grimaldi M., Alvarez S., de Lera A.R., et al. A unique secondary structure switch controls constitutive gene repression by retinoic acid receptor. Nat. Struct. Mol. Biol. 2010, 17:801-807.
41. Li H., Gomes P.J., Chen J.D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. USA 1997, 94:8479-8484.
42. Loeliger P., Bollag W., Mayer H. Arotinoids: A new class of highly active retinoids. Eur. J. Med. Chem. 1980, 15:9-15.
43. Lonard D.M., O'Malley B.W. Nuclear receptor coregulators: Judges, juries, and executioners of cellular regulation. Mol. Cell 2007, 27:691-700.
44. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: Cellular and molecular biology. Endocr. Rev. 1999, 20:321-344.
45. Melnick A., Carlile G., Ahmad K.F., Kiang C.L., Corcoran C., Bardwell V., et al. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol. Cell Biol. 2002, 22:1804-1818.
46. Memic A., Spaller M.R. How do halogen substituents contribute to protein-binding interactions? A thermodynamic study of peptide ligands with diverse aryl halides. ChemBioChem 2008, 9:2793-2795.
47. Nagpal S., Friant S., Nakshatri H., Chambon P. RARs and RXRs: Evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J. 1993, 12:2349-2360.
48. Nagy L., Schwabe J.W. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 2004, 29:317-324.
49. Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997, 89:373-380.
50. Nagy L., Kao H.Y., Love J.D., Li C., Banayo E., Gooch J.T., et al. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 1999, 13:3209-3216.
51. Nahoum V., Pérez E., Germain P., Rodríguez-Barrios F., Manzo F., Kammerer S., et al. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc. Natl. Acad. Sci. USA 2007, 104:17323-17328.
52. Nofsinger R.R., Li P., Hong S.H., Jonker J.W., Barish G.D., Ying H., et al. SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. Proc. Natl. Acad. Sci. USA 2008, 105:20021-20026.
53. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87:953-959.
54. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
55. Pérez-Santín E., Germain P., Quillard F., Khanwalkar H., Rodríguez-Barrios F., Gronemeyer H., et al. Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5, 5, 8, 8-tetramethyl-5, 6, 7, 8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers. J. Med. Chem. 2009, 52:3150-3158.
56. Perissi V., Staszewski L.M., McInerney E.M., Kurokawa R., Krones A., Rose D.W., et al. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 1999, 13:3198-3208.
57. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: A coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
58. Sande S., Privalsky M.L. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol. Endocrinol. 1996, 10:813-825.
59. Seol W., Mahon M.J., Lee Y.K., Moore D.D. Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR. Mol. Endocrinol. 1996, 10:1646-1655.
60. Takeshita A., Cardona G.R., Koibuchi N., Suen C.S., Chin W.W. TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J. Biol. Chem. 1997, 272:27629-27634.
61. Torchia J., Rose D.W., Inostroza J., Kamei Y., Westin S., Glass C.K., et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1996, 387:677-684.
62. Voegel J.J., Heine M.J., Zechel C., Chambon P., Gronemeyer H. TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996, 15:3667-3675.
63. Voegel J.J., Heine M.J., Tini M., Vivat V., Chambon P., Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 1998, 17:507-519.
64. Westin S., Rosenfeld M.G., Glass C.K. Nuclear receptor coactivators. Adv. Pharmacol. 2000, 47:89-112.
65. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002, 415:813-817.
66. Yao T.P., Ku G., Zhou N., Scully R., Livingston D.M. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc. Natl. Acad. Sci. USA 1996, 93:10626-10631.
67. Zamir I., Harding H.P., Atkins G.B., Horlein A., Glass C.K., Rosenfeld M.G., et al. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol. Cell. Biol. 1996, 16:5458-5465.
68. Zhang J., Hu X., Lazar M.A. A novel role for helix 12 of retinoid X receptor in regulating repression. Mol. Cell. Biol. 1999, 19:6448-6457.